Dilution tracker test, round 1: Signal8 matched 10 of 10
In round 1 of our dilution tracker test, Signal8 matched the SEC filing on every figure: DilutionScan Pro and the Signal8 dilution tab each showed all 10 filings with figures matching the filing, tied for the top result with AskEdgar Pro, which also matched on 10 of 10. DilutionWatch's free trackers matched 8 of 10. DilutionScan costs $29.99 a month and AskEdgar Pro $59 (vendor list prices).
Plan tested: Signal8 products and AskEdgar on paid plans, DilutionWatch and EDGAR free (see the "Plan tested" column). This is not like for like: free Signal8 views sit beside paid plans, and each tool was checked at a different hour. 10 filings. Signal8 runs this site.
| Tool | Plan tested | Filing shown | Partly | Not shown | Figures shown and matching | Figures paywalled | Shown, no figure |
|---|---|---|---|---|---|---|---|
| SEC EDGAR | Free public site | 10 | 0 | 0 | 10 | 0 | 0 |
| Signal8 dilution tab (paid-tier data) | Signal8 dilution tab, founder's signed-in admin account (instrument figures visible; the AI summary on the same page still shows Upgrade to Pro). Paid-tier data, our product. | 10 | 0 | 0 | 10 | 0 | 0 |
| DilutionScan Pro (paid) | Pro (paid). DilutionScan signed in as [email protected], the founder's own account, with Pro shown in the account menu and no Pro locks on the page. Checked about three to four hours after the free views. Our product. | 10 | 0 | 0 | 10 | 0 | 0 |
| Signal8 free dilution summary | Signal8 free public dilution summary, signed out. Our product. | 8 | 0 | 2 | 0 | 0 | 8 |
| DilutionScan (free view) | DilutionScan free view, signed out. Our product. Its Pro plan is tested in its own row. | 8 | 1 | 1 | 0 | 9 | 0 |
| DilutionWatch (guest and public trackers) | DilutionWatch guest view and public trackers, free, no account | 8 | 0 | 2 | 8 | 0 | 0 |
| AskEdgar | AskEdgar Pro (paid; published list price $59 a month, askedgar.io/pricing, checked Nov 9). Read on the founder's signed-in account, Filings and Dilution pages of the Classic app. A competitor's paid plan. | 10 | 0 | 0 | 10 | 0 | 0 |
| DilutionTracker | Not tested | Not tested. The test browser is signed in to a DilutionTracker account whose plan we could not confirm as free, so we did not use what it showed. | |||||
| Dilutracker | Not tested | Not tested, paywalled. No free plan is listed on its pricing page. | |||||
| Fintel | Not tested | Not tested. Fintel showed a bot verification page to the test browser and never loaded. | |||||
Raw data, one row per filing and tool: round-1.csv.
Free views: what they show
- The free Signal8 views list the instruments; the figures are in Pro. Signal8's free summary showed 8 of 10 filings and DilutionScan's free view 8 (1 partly), each citing the filing, with dollar and share amounts kept for Pro.
- Two filings were not in the free summaries at check time (Big Digital Energy's resale S-3 and Auddia's warrant exchange 8-K), for Signal8 and DilutionWatch alike. DilutionScan's NaaS Technology analysis predated its F-3 shelf at the free check; it updated on November 9, and Pro showed the shelf.
- AskEdgar Pro showed all 10 filings with figures matching the filing, including Big Digital Energy's resale S-3 and Auddia's warrant exchange 8-K, which the free Signal8 summaries and DilutionWatch did not have at check time. On aTyr, Signal8 Pro shows the $215.0M program total beside the $80M capacity; AskEdgar showed the capacity alone. AskEdgar's pricing page lists dilution and offering data as not included on its free plan (askedgar.io/pricing, checked Nov 9).
BioVie: which ATM figure is right
BioVie's 10-Q (filed November 6) describes its September 11, 2026 sales agreement with A.G.P. as up to $6,464,341. Signal8, DilutionScan Pro, AskEdgar Pro and DilutionWatch all show $285K. We first scored $285K as wrong. Reading the prospectus supplements changed that: Amendment No. 2 to the prospectus supplement (424B5, accession 0001520138-26-000454, filed November 5, 2026) reduced the program "to up to an aggregate of $285,000", after Amendment No. 1 (November 4) had cut it to $1,225,000. The same amendment states about $282,958 had been sold, so roughly $2,000 remains. The 10-Q restates the original size. We now score the four tools as matching on the current program size, and the reference column says which measure it uses.
Scope
Each tool was checked once, two to three days after SEC acceptance, so this round measures accuracy, not speed; acceptance times are in the table for the latency round. DilutionTracker, Dilutracker and Fintel were not tested (reasons in the table). AskEdgar was read on a paid Pro account, so its row is a paid-plan row like ours; no plan was bought for this test.
The 10 filings, tool by tool
| Filing | What the filing says | SEC EDGAR | Signal8 dilution tab (paid-tier data) | DilutionScan Pro (paid) | Signal8 free dilution summary | DilutionScan (free view) | DilutionWatch (guest and public trackers) | AskEdgar |
|---|---|---|---|---|---|---|---|---|
| USGO 424B5 (ATM supplement) 0001493152-26-050486 Accepted 2026-11-06 16:34:55 ET | ATM capacity reduced to $3,200,000 of common stock (H.C. Wainwright and co-agents) | Shown Source The filing itself, public at acceptance. | Shown Matches Dilution tab: ATM $3.2M capacity, H.C. Wainwright lead agent. | Shown Matches ATM section: H.C. Wainwright lead agent, $3,200,000 capacity. Latest event: ATM sale, Nov 6. | Shown No figure shown Free summary ATM row cites this 424B5. | Shown Paywalled Latest event: ATM sale, Nov 6. Capacity figures need Pro. | Shown Matches Shelf and ATM monitor shows ATM $3M (rounded). | Shown Matches Filings and Dilution pages list the Nov 2026 ATM: $3.2M, H.C. Wainwright & Co. (co-agents not named). Filed Nov 6. |
| ATYR 424B5 (ATM supplement) 0001339970-26-000083 Accepted 2026-11-06 16:05:21 ET | ATM amended and restated: up to $79,994,251 of common stock (program total $215.0 million incl. $65.0 million already sold), Jefferies | Shown Source The filing itself, public at acceptance. | Shown Matches ATM $215M authorised, $80M continuous capacity, Jefferies. | Shown Matches Jefferies ATM: $215,000,000 authorised, $79,994,251 remaining capacity. | Shown No figure shown ATM row cites this 424B5. | Shown Paywalled Latest event: ATM sale, Nov 6. | Shown Matches Shows ATM $80M (rounded). | Shown Matches Filings lists the 424B5 and the 8-K (Nov 6). Dilution page: Nov 2026 ATM $79.99M, Jefferies. The $215.0M program total and the $65.0M already sold were not shown on the pages read. |
| FATE 424B5 (ATM supplement) 0001193125-26-450013 Accepted 2026-11-05 16:36:46 ET | New ATM: up to $100,000,000 of common stock through Leerink Partners | Shown Source The filing itself, public at acceptance. | Shown Matches Leerink Partners ATM dated Nov 5, 2026, $100.0M capacity. | Shown Matches Leerink Partners Sales Agreement ATM (November 2026), $100,000,000. | Shown No figure shown ATM row cites this 424B5. | Shown Paywalled Latest event: ATM sale, Nov 5. | Shown Matches Shows ATM $100M and shelf $300M. | Shown Matches Filings lists the 424B5 and 8-K (Nov 5). Dilution page: Nov 2026 ATM $100M, Leerink Partners; the Jefferies agreement is marked replaced. |
| BIVI 10-Q (discloses ATM) 0001520138-26-000461 Accepted 2026-11-06 17:15:59 ET 424B5 Amendment No. 2 | A.G.P. ATM under the Sales Agreement of September 11, 2026. Reference measure: current program size, up to $285,000, per Amendment No. 2 to the prospectus supplement (424B5, 0001520138-26-000454, filed November 5, 2026), of which about $282,958 had been sold. The 10-Q restates the original size, up to $6,464,341, which that amendment reduced. | Shown Source The filing itself, public at acceptance. | Shown Matches Shows the A.G.P. ATM dated Sep 11, 2026 with $285K capacity and $282,958 sold, matching Amendment No. 2. First scored as differing against the 10-Q figure; corrected after reading the amendment. | Shown Matches A.G.P. ATM dated Sep 11, 2026: $285.0K total capacity, $283.0K sold to date (as of Nov 4). Matches the program size after Amendment No. 2. | Shown No figure shown ATM row cites this 10-Q. | Partly Paywalled Counts 2 ATM programs, but analysis dated Nov 5, before this 10-Q. | Shown Matches Shows ATM $285K, matching Amendment No. 2. First scored as differing against the 10-Q figure; corrected after reading the amendment. | Shown Matches Dilution page shows the amendment chain $6,464,341, then $1,225,000, then $285,000 (A.G.P., Nov 4); current program size $285K matches the reference. The 10-Q is listed in Filings. |
| BGDE S-3 (resale) 0001213900-26-117011 Accepted 2026-11-06 17:30:05 ET | Resale registration of up to 442,899 common shares held by Endeavor Blockchain, LLC | Shown Source The filing itself, public at acceptance. | Shown Matches Resale registration filed Nov 6: 443K shares registered. | Shown Matches Latest event: resale registration filed Nov 6, 442,899 shares (Form S-3). | Not shown Summary regenerated after the filing, but its shelf row still cites an August 424B3; the S-3 is not cited. | Shown Paywalled Latest event: registration, Nov 6. | Not shown No resale registration shown on the public trackers. | Shown Matches Filings lists the S-3 (Nov 6). Dilution page: pending share resale registration, 442.9K shares (rounded); the holder column was blank. |
| PPBT F-3/A (shelf) 0001614744-26-000003 Accepted 2026-11-06 17:08:22 ET | Shelf: securities with a maximum aggregate offering price of $200,000,000 | Shown Source The filing itself, public at acceptance. | Shown Matches Shelf tab: November 2026 shelf, not yet effective, $200M total capacity. | Shown Matches Shelf section: F-3 333-296088, $200M, filed and not yet effective. | Shown No figure shown Shelf row cites this F-3/A. | Shown Paywalled An event dated Nov 6 is shown, labelled ATM sale rather than shelf amendment. | Shown Matches Shows shelf $200M. | Shown Matches Filings lists the F-3/A (Nov 6). Dilution page: pending May 2026 shelf and ATM, $200M, matches the shelf figure. |
| NAAS F-3 (shelf) 0001185185-26-005239 Accepted 2026-11-06 16:30:44 ET | Shelf: up to US$200,000,000 of securities | Shown Source The filing itself, public at acceptance. | Shown Matches Most recent event: shelf registration filed Nov 6, $200M. | Shown Matches Latest event: F-3 shelf filed Nov 6, up to $200M. Its analysis was updated Nov 9, after the free-view check, which still saw the Oct 7 analysis. | Shown No figure shown Shelf row cites this F-3. | Not shown Analysis last updated Oct 7; latest event shown is Aug 31. | Shown Matches Shows shelf $200M. | Shown Matches Filings lists the F-3 (Nov 6). Dilution page: pending Nov 2026 shelf, $200M; the row is dated Nov 5, 7:00 PM, a day before SEC acceptance. |
| AUUD 8-K Items 1.01, 3.02 (warrants) 0001683168-26-008388 Accepted 2026-11-06 17:16:50 ET | Warrant exchange: 580,023 existing warrants exchanged for 1,160,045 common shares, plus 4,135,539 more warrants for 8,271,077 shares subject to stockholder approval | Shown Source The filing itself, public at acceptance. | Shown Matches Exchange for warrants: 1,160,045 shares, Nov 6. | Shown Matches Latest event: exchange for warrants, 1,160,045 common shares, Nov 6. | Not shown Summary regenerated November 8 still cites the August 10-Q; the 8-K is not cited. | Shown Paywalled Latest event: exchange, Nov 6. | Not shown Warrant exchange not shown; warrant tracker still lists 5.1M warrants. | Shown Matches Filings lists the 8-K (Nov 6). Warrant note: 580,023 warrants exchanged at 2 shares per warrant, 4,135,539 more after stockholder approval. Resulting share totals not stated. |
| RENX 8-K Items 1.01, 3.02 (note and warrant) 0001213900-26-116998 Accepted 2026-11-06 17:15:52 ET | $1,022,971.22 of debt exchanged for a $1,037,283.93 senior convertible note (initial conversion price $2.895) and a warrant for 644,944 shares at $2.67 | Shown Source The filing itself, public at acceptance. | Shown Matches Note $1.04M principal, warrant for 645K shares at $2.67, Nov 2. | Shown Matches Alto exchange note, $1,037,283.93 principal; warrant for 644,944 shares at $2.67; Nov 2. | Shown No figure shown Latest offering row cites this 8-K. | Shown Paywalled Latest event: offering, Nov 2 (agreement date). | Shown Matches PIPE tracker: convertible Nov 2, $1M, 645K shares, $2.90. | Shown Matches Filings lists the 8-K (Nov 6). Dilution page: note $1,037,283.93 at $2.895 conversion, warrant 644,944 at $2.67. |
| SILO 8-K Items 1.01, 3.02 (private placement) 0001213900-26-116982 Accepted 2026-11-06 17:08:05 ET | Private placement: 136,005 shares at $1.50 plus pre-funded warrants for 430,661 shares | Shown Source The filing itself, public at acceptance. | Shown Matches PIPE: 136K shares at $1.50, 431K pre-funded warrant shares, Nov 6. | Shown Matches PIPE: 136,005 shares at $1.50 plus pre-funded warrants for 430,661 shares, Nov 6. | Shown No figure shown Latest offering row cites this 8-K. | Shown Paywalled Latest event: offering, Nov 6. | Shown Matches PIPE tracker: private placement Nov 5, 136K shares at $1.50 (total shown $815K). | Shown Matches Filings lists the 8-K (Nov 6). Dilution page: private placement 566.67K shares at $1.50 (rounded; filing: 136,005 shares plus 430,661 pre-funded warrants) and 430,661 pre-funded warrants. |
Method
- Pick. From this site's own ATM, shelf and warrant trackers as built on 2026-11-09: the 4, 3 and 3 most recent rows whose company has a published Signal8 dilution snapshot (our proxy for small cap; we do not show market caps). No filing was swapped out after checking.
- Reference figures. Each reference figure is the filing's own figure, read on EDGAR (accession numbers are in the table and CSV), with the EDGAR acceptance time. We then checked every one line by line against Signal8's dilution tab. The filing is the authority. Where a later filing changes a figure, the later filing wins and the reference says which measure it uses: BioVie's ATM is scored on its size after the November 5 amendment, not the original size the 10-Q restates. The cross-check also caught one error in our own key (Auddia's exchange is 1,160,045 shares, not 1,160,046), which we corrected against the filing, not against Signal8.
- Plans. Signal8's dilution tab was read on the founder's signed-in admin account, where instrument figures are visible (its AI summary still shows an upgrade prompt). DilutionScan Pro was read signed in as [email protected] with Pro shown on the account. AskEdgar Pro was read signed in on a paid account, on the Filings and Dilution pages of its Classic app (the plan name was read from the account page; published list price $59 a month, askedgar.io/pricing, checked Nov 9). DilutionWatch and EDGAR were read free and signed out. No plan was bought for this test.
- Check. Each tool's pages on the plan stated in the table, 2026-11-09 04:55 to 06:10 UTC (Signal8 dilution tab: 07:05 to 07:25 UTC; DilutionScan Pro: 09:05 to 09:15 UTC; AskEdgar Pro: about 11:10 to 11:15 UTC). Shown means the filing or its event appears for that company; matching means a figure shown agrees with the filing, allowing rounding.
- Disclosure. Signal8, which runs this site, makes the Signal8 dilution tab, the Signal8 summary and DilutionScan.
The next round adds hourly checks from SEC acceptance (latency) and competitors' paid tiers, as set out in the benchmark protocol.